Search Results - does

1412 Results

Sort By:

Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy

Summary: The National Cancer Institute (NCI) seeks capable licensees interested in commercializing T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors. Description of Technology: TCR-T therapies, particularly those targeting patient-specific neoantigens, remain a promising approach to the treatment metastatic cancers....

Published: 8/25/2025 | Inventor(s): Steven Feldman, Steven Rosenberg, Drew Deniger

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a set of Chimeric Antigen Receptors (CARs) that target the γδ T-Cell Receptor. Description of Technology: T cells express two main types of receptors based on the proteins that make up the T-cell receptor (TCR) heterodimers: ab (alpha...

Published: 8/25/2025 | Inventor(s): James Kochenderfer, Lauren Cutmore

Keywords(s):

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s)

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for development of papilloma-infiltrating lymphocytes (PIL) as treatment for patients with chronic human papillomavirus (HPV) 6 or 11 infections. Description of Technology: Recurrent Respiratory Papillomatosis (RRP) and anogenital condyloma are caused...

Published: 8/21/2025 | Inventor(s): Scott Norberg, Clint Allen, Zulmarie Franco, Ke Bai

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof

Summary: The National Cancer Institute (NCI) and Frederick National Laboratory for Cancer Research (FNLCR) seek research co-development partners and/or licensees for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for recurrent respiratory papillomatosis (RRP). Description of Technology: Recurrent...

Published: 8/21/2025 | Inventor(s): Scott Norberg, Clint Allen, Xiaolin Wu

Keywords(s):

Category(s): TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, TherapeuticArea > Pulmonology, Application > Diagnostics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

C8166-45 Cells

Summary: The National Cancer Institute (NCI) seeks licensees for a human T-cell line, C8166-45, transformed by HTLV-1. C8166-45, also known as C63/CRII-2, contains three transcriptionally active proviruses useful for testing biological activities involved in T-cell immortalization and growth. Description of Technology: ...

Published: 8/21/2025 | Inventor(s): Genoveffa Franchini, Syed Salahuddin, Flossie Wong-Staal, Robert Gallo, Phillip Markham, V Kalyanaraman

Keywords(s):

Category(s): Application > Research Materials, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Chimeric VLP vaccines to Prevent HTLV-1 Infection

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for Chimeric VLP Vaccines to Prevent HTLV-1 Infection. Description of Technology: There is currently no approved vaccine to prevent human T-cell leukemia virus type I (HTLV-1) infection, a highly oncogenic virus linked to serious diseases like adult...

Published: 8/12/2025 | Inventor(s): Genoveffa Franchini, Sarkis Sarkis, Ramona Moles, Cynthia Masison, Massimiliano Bissa

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies

Summary: The National Cancer Institute (NCI) seeks licensees for this invention comprising (1) a novel T cell receptor (TCR) specific to the E2 protein of Human papillomavirus (HPV) type 6 in the context of the human leukocyte antigen, HLA-B55, and (2) a panel of Cos7 cells expressing different HLA proteins for validation of T cell responses in immunotherapies...

Published: 8/21/2025 | Inventor(s): Clint Allen, Scott Norberg

Keywords(s):

Category(s): Application > Research Materials, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Collaboration Sought > Licensing

A conserved viral peptide for use in cancer immunotherapy

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for viral peptide (CE1)-based therapeutics for HCC prevention and treatment. Description of Technology: Hepatocellular carcinoma (HCC) is a common and aggressive primary liver cancer. It develops mainly from at-risk individuals with underlying chronic...

Published: 8/21/2025 | Inventor(s): Xin Wei Wang, Lichun Ma, Man Hsin Hung

Keywords(s):

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy

Summary: The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for NCI’s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines. Description of Technology: Current dendritic cell (DC)-based cancer vaccines are limited by impaired DC function due to cancer-driven...

Published: 8/21/2025 | Inventor(s): Jay Berzofsky, Shweta Tiwary

Keywords(s):

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1

Summary: The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is actively seeking potential licensees interested in further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases. Description of Technology: Cellular...

Published: 8/21/2025 | Inventor(s): Paul Love, Avik Dutta

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology

1 2 3 4 5 6 7 8 9 10 ...